Can-Fite Submits Phase III Protocol to IRB for CF101 in the Treatment of Rheumatoid Arthritis

Can-Fite BioPharma Ltd. (NYSE MKT:

) announced today an important milestone towards beginning the pivotal Phase III trial of its lead drug candidate CF101 in the treatment of rheumatoid arthritis. Can-Fite has submitted its Phase III clinical study protocol to the Institutional Review Board (IRB) of Barzilai Medical Center in Israel and will file similar submissions in several European countries, Canada and the U.S. The Phase III protocol submission in Israel follows a successful meeting that Can-Fite concluded on December 8, 2015 with the Medical Products Agency (MPA) in Sweden regarding the European registration of CF101 in the treatment of rheumatoid arthritis. During the meeting, Can-Fite presented data from the Company's successful Phase II trial in rheumatoid arthritis and the CF101 rheumatoid arthritis clinical registration strategy was discussed.